Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016
Published Sep 21, 2016
57 pages — Published Sep 21, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016, provides in depth analysis on Calcitonin Gene Related Peptide (CGRP) targeted pipeline therapeutics.

The report provides comprehensive information on the Calcitonin Gene Related Peptide (CGRP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
- The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new cli

  
Source:
Document ID
GMDHC0529TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Calcitonin Gene Related Peptide (CGRP) Overview61
Therapeutics Development73
  Calcitonin Gene Related Peptide (CGRP) Products under Development by Stage of Development71
  Calcitonin Gene Related Peptide (CGRP) Products under Development by Therapy Area81
  Calcitonin Gene Related Peptide (CGRP) Products under Development by Indication91
Calcitonin Gene Related Peptide (CGRP) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Calcitonin Gene Related Peptide (CGRP) Products under Development by Companies122
Calcitonin Gene Related Peptide (CGRP) Therapeutics Assessment146
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration162
  Assessment by Molecule Type182
Calcitonin Gene Related Peptide (CGRP) Companies Involved in Therapeutics Development205
  Alder Biopharmaceuticals Inc.201
  Boehringer Ingelheim GmbH211
  Eli Lilly and Company221
  Noxxon Pharma AG231
  Teva Pharmaceutical Industries Ltd.241
Calcitonin Gene Related Peptide (CGRP) Drug Profiles2513
  ALD-403 Drug Profile254
  galcanezumab Drug Profile292
  NOXL-41 Drug Profile311
  olcegepant Drug Profile321
  Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain Drug Profile331
  TEV-48125 Drug Profile344
Calcitonin Gene Related Peptide (CGRP) Dormant Projects382
Calcitonin Gene Related Peptide (CGRP) Discontinued Products401
Calcitonin Gene Related Peptide (CGRP) Featured News &Press Releases4115
  Sep 08, 2016: Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention411
  Sep 06, 2016: Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer411
  Jul 25, 2016: Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine421
  Jun 09, 2016: Alder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society431
  Jun 08, 2016: New drug to prevent migraine may start working in days441
  Jun 02, 2016: Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention451
  May 25, 2016: Alder BioPharmaceuticals Continues to Strengthen and Expand Leadership Team to Support Advancement of ALD403 for Migraine Prevention461
  Apr 12, 2016: Teva to Present Data on TEV-48125 at 68th AAN Annual Meeting471
  Mar 28, 2016: Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine472
  Feb 09, 2016: Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization491
  Oct 13, 2015: Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine501
  Sep 30, 2015: Important New Data from Teva's TEV-48125 Phase 2B Migraine Program Published in Lancet Neurology in Back-to-Back Articles511
  Jun 18, 2015: Teva to Present New Findings at the American Headache Society Meeting Analysis of Migraine Phase IIb Studies Provides Novel Insights into TEV-48125 Efficacy and Safety in Both Episodic &Chronic Migraine522
  Jun 17, 2015: Lilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study541
  May 15, 2015: Alder Presents Positive Clinical Data for ALD403 at the 17th Congress of the International Headache Society551
Appendix562
  Methodology561
  Coverage561
  Secondary Research561
  Primary Research561
  Expert Panel Validation561
  Contact Us561
  Disclaimer571

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016" Sep 21, 2016. Alacra Store. May 07, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Calcitonin-Gene-Related-Peptide-CGRP-Pipeline-Review-H2-2016-2088-16587>
  
APA:
Global Markets Direct - Market Research. (2016). Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2016 Sep 21, 2016. New York, NY: Alacra Store. Retrieved May 07, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Calcitonin-Gene-Related-Peptide-CGRP-Pipeline-Review-H2-2016-2088-16587>
  
US$ 3,500.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.